FIELD: chemistry.
SUBSTANCE: invention relates to a new crystalline polymorph of 3-(N-methyl-N-pentyl)amino-1-hydroxypropane-1,1-diphosphonic acid monosodium salt monohydrate (Ibandronate) with formula I, which is characterised by x-ray powder diffraction pattern with characteristic peaks at angles 2-theta: 9.7°, 12.2°, 14.4°, 16.8° and 25.8°, IR-spectrum with characteristic peaks, cm-1: 3679, 3164, 2955; 2854, 1377, 1290, 1157, 1093, 1068, 1035, 965, 951, 933, 905, 761 and 723, as well as a vibrational Raman spectrum with characteristic peaks, cm-1: 2968, 2951, 2928, 2887, 2849, 1441, 1308, 1136, 1056, 1023, 954, 907, 839, 762 and 678. 
formula I.
EFFECT: obtaining a new crystalline ibandronate polymorph used for controlling hypercalcemia, having improved solubility.
13 cl, 6 dwg, 6 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| POLYMORPHIC MODIFICATION OF A IBANDRONATE | 2006 |
|
RU2368617C2 |
| CRYSTALLINE FORM OF ASENAPINE MALEATE | 2006 |
|
RU2405786C2 |
| CRYSTALLINE MODIFICATIONS OF HYDROCHLORIDE (-)-(1R, 2R)-3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYLPROPYL)PHENOL | 2005 |
|
RU2423345C2 |
| CRYSTAL SUBSTANCE OF HETEROCYCLIDENACETAMIDE DERIVATIVE | 2018 |
|
RU2779198C2 |
| 4-[2-[[5-METHYL-1-(2-NAPHTHALINYL)-1H-PYRAZOL-3-YL]OXY]ETHYL]MORPHOLINE HYDROCHLORIDE POLYMORPH AND SOLVATES | 2011 |
|
RU2560150C2 |
| METHOD OF MODIFYING CRYSTALLISATION PROCESS OF MEDICINAL SUBSTANCE | 2004 |
|
RU2388757C2 |
| 3-[2-(DIMETHYLAMINO)METHYL-(CYCLOHEX-1-YL)]PHENOL MALEATE AND ITS CRYSTALLINE FORMS | 2006 |
|
RU2434845C2 |
| POLYMORPHOUS MODIFICATION OF COMPOUND {6,7-BIS (2-METHOXYETHOXY)CHINAZOLINE-4-YL}-(3e) | 2004 |
|
RU2376294C2 |
| STABLE MODIFICATIONS OF TEGASEROD HYDROMALEATE | 2004 |
|
RU2349585C2 |
| CRYSTALLINE MODIFICATIONS | 2005 |
|
RU2400479C2 |
